Post progression survival analysis of metastatic gastric and gastroesophageal junction cancer patients after second-line treatment

被引:0
|
作者
Turkmen, Esma [1 ]
Erdogan, Bulent [1 ]
Kodaz, Hilmi [1 ]
Hacibekiroglu, Ilhan [1 ]
Onal, Yilmaz [2 ]
Uzunoglu, Sernaz [1 ]
Kilic, Nilufer [3 ]
Cicin, Irfan [1 ]
机构
[1] Trakya Univ, Fac Med, Dept Med Oncol, Edirne, Turkey
[2] Trakya Univ, Fac Med, Dept Internal Med, Edirne, Turkey
[3] Trakya Univ, Fac Med, Dept Radiat Oncol, Edirne, Turkey
关键词
metastatic gastric cancer; post progression survival; overall survival performance status; second-line treatment; RANDOMIZED PHASE-III; SUPPORTIVE CARE; CHEMOTHERAPY; COMBINATION; STATISTICS; IRINOTECAN; PLUS;
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Purpose : The aim of this study was to define the factors that affect response and post-progression survival of metastatic gastric cancer (MGC) and gastroesophageal junction cancer (GEJ) patients treated with second-line chemotherapy. Methods : We retrospectively reviewed the data of 59 patients with MGC or GEJ adenocarcinoma who received second-line treatment. Results : The median age was 54 years old (26-77). Response to second-line treatment was strongly associated with disease control with first-line treatment (p < 0.01). Median progression-free survival (PFS), overall survival (OS) and post-progression survival (PPS) were 3.2 (95% CI : 2.63-3.80), 6.5 (95% CI : 3.78-9.35) and 2.7 months (95% CI : 1.89-3.68), respectively. PFS (r = 0.55, p < 0.01) and PPS (r = 0.89, p < 0.01) were correlated with OS. Response to second-line treatment was independently related to PFS (HR : 0.12 95% CI : 0.53-0.26, p < 0.001). Having an ECOG 0 performance status (HR : 0.42; 95% CI : 0.21-0.86, p = 0.02) and response to second-line therapy (HR : 0.47; 95% CI : 0.25-0.85, p = 0.01) were independently associated with OS. Conclusion : PPS and PFS were correlated with OS after second-line treatment of MGC. Response to second-line treatment prolonged OS by increasing PFS, and having an ECOG 0 PS prolonged OS by increasing PPS.
引用
收藏
页码:211 / 215
页数:5
相关论文
共 50 条
  • [41] Prognostic factors in metastatic gastric cancer patients (pts) treated with second-line chemotherapy
    Catalano, V.
    Graziano, F.
    Santini, D.
    Baldelli, A. M.
    Giordani, P.
    Vincenzi, B.
    Rossi, D.
    Alessandroni, P.
    Tonini, G.
    Catalano, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [42] Clinical experience: Ramucirumab with FOLFIRI/XELIRI as a second-line for patients with metastatic gastric cancer
    Titova, T.
    Besova, N.
    Artamonova, E.
    Perminova, E.
    ANNALS OF ONCOLOGY, 2019, 30 : 309 - 309
  • [43] Prognostic factors in advanced gastric cancer after second-line treatment.
    Longo, Federico
    Pachon, Vanessa
    Guillen, Carmen
    Ferreiro, Reyes
    Rodriguez Garrote, Mercedes
    Reguera Puertas, Pablo
    Madariaga, Ainhoa
    Gion, Maria
    Lopez Hervas, Pedro
    Galindo, Julio
    Gonzalez Lizarbe, Eva
    Varona, Constantino
    Montans, Jose
    Earl, Julie
    Grande, Enrique
    Olmedo Garcia, Maria Eugenia
    Garrido, Pilar
    Lobo, Eduardo
    Palacios, Jose
    Carrato, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [44] Anlotinib Combined with Toripalimab as Second-Line Therapy for Advanced, Relapsed Gastric or Gastroesophageal Junction Carcinoma
    Jiang, Man
    Zhang, Chuantao
    Hu, Yabin
    Li, Tianjun
    Yang, Guangjie
    Wang, Guanqun
    Zhu, Jingjuan
    Shao, Changfeng
    Hou, Helei
    Zhou, Na
    Liu, Kewei
    Zhang, Xiaochun
    ONCOLOGIST, 2022, 27 (11): : E856 - E869
  • [45] Impact of muscle mass loss on outcomes in advanced or metastatic gastric cancer patients receiving a second-line treatment
    Zurlo, V.
    Rosa, F.
    Rinninella, E.
    Pontolillo, L.
    Beccia, V.
    Maratta, M.
    Tortora, G.
    Alfieri, S.
    Pozzo, C.
    Strippoli, A.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2024, 28 (04) : 1575 - 1584
  • [46] Phase I/II Study of Weekly Oraxol for the Second-Line Treatment of Patients With Metastatic or Recurrent Gastric Cancer
    Lee, Keun-Wook
    Lee, Kyung Hee
    Zang, Dae Young
    Park, Young Iee
    Shin, Dong Bok
    Kim, Jin Won
    Im, Seock-Ah
    Koh, Sung Ae
    Yu, Kyung-Sang
    Cho, Joo-Youn
    Jung, Jin-A
    Bang, Yung-Jue
    ONCOLOGIST, 2015, 20 (08): : 896 - 897
  • [47] Second-line treatments in metastatic gastric cancer: Pooled analysis of randomized clinical trials
    Fantini, Manuela
    Stocchi, Lucia
    Nicoletti, Stefania
    Tamburini, Emiliano
    Fabbri, Paolo
    Polselli, Antonio
    Drudi, Fabrizio
    Affatato, Alessandra
    Gianni, Lorenzo
    Tassinari, Davide
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [48] Paclitaxel With or Without Cixutumumab as Second-Line Treatment of Metastatic Esophageal or Gastroesophageal Junction Cancer: A Randomized Phase II ECOG-ACRIN Trial
    Stockton, Shannon
    Catalano, Paul
    Cohen, Steven J.
    Burtness, Barbara A.
    Mitchell, Edith P.
    Dotan, Efrat
    Lubner, Sam J.
    Kumar, Pankaj
    Mulcahy, Mary F.
    Fisher, George A.
    Crandall, Theodore L.
    Benson, Al
    ONCOLOGIST, 2023, 28 (09): : 827 - +
  • [49] Second-line treatment of metastatic gastric cancer in the era of predictive biomarkers: A cost-effectiveness analysis.
    Lauren, Brianna
    Silver, Elisabeth
    Ingram, Myles
    Oh, Aaron
    Kumble, Lindsay
    Ostvar, Sassan
    Laszkowska, Monika
    Chu, Jacqueline N.
    Manji, Gulam Abbas
    Neugut, Alfred I.
    Hur, Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [50] Evaluation of safety of bevacizumab as second-line treatment of patients with metastatic colorectal cancer
    Todorovic, Vladimir
    Saric, Nada Cicmil
    Lakicevic, Jadranka
    Sorat, Milan
    JOURNAL OF BUON, 2017, 22 (05): : 1131 - 1136